验证平均偏差变化率作为青光眼进展临床相关终点指标
本研究为纵向前瞻性观察研究,纳入168例青光眼患者的246只眼,每6个月随访至5年。结果显示,初始2年标准自动视野计平均偏差(MD)变化率可强烈预测后续视野进展事件,支持将MD变化斜率作为临床试验中合适的进展终点。
要点
- 初始2年每快0.1 dB/年的MD丢失,与GPA进展终点风险增加26%相关(R²=76%)。
- 初始2年每快0.1 dB/年的MD丢失,与FDA终点风险增加32%相关(R²=83%)。
- 初始2年MD变化率降低30%与5年随访期间进展事件累积概率降低20%相关。
核心结论
- 青光眼眼初始2年随访期间计算的标准自动视野计MD变化率可强烈预测后续随访中的进展事件。
- 研究结果支持将MD变化斜率作为临床试验中合适的进展终点。
研究设计与样本
- 纵向、前瞻性、观察性研究。
- 纳入168例青光眼患者的246只眼,每6个月随访一次,最长随访5年。
- 要求患者在前2年随访期间至少有5次可靠的标准自动视野计检查。
- 采用引导进展分析(GPA)和美国食品药品监督管理局(FDA)建议的终点两种方法评估进展事件。
- 采用联合纵向生存模型评估初始MD丢失速度与后续进展风险的关系。
主要发现
- 56只眼(22.8%)通过GPA显示进展事件,51只眼(20.7%)通过FDA终点显示进展事件。
- 初始2年每快0.1 dB/年的标准自动视野计MD丢失,与GPA进展终点风险增加26%相关(R²=76%)。
- 初始2年每快0.1 dB/年的标准自动视野计MD丢失,与FDA终点风险增加32%相关(R²=83%)。
- 初始2年MD变化率降低30%与5年随访期间进展事件累积概率降低20%相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether rates of standard automated perimetry (SAP) mean deviation (MD) over an initial 2-year follow-up period were predictive of events of visual field progression over an extended follow-up. DESIGN: Longitudinal, prospective, observational study. PARTICIPANTS: Two hundred forty-six eyes of 168 patients with glaucoma followed up every 6 months for up to 5 years. METHODS: Patients were required to have a minimum of 5 reliable SAP tests during the first 2 years of follow-up. Events of progression were evaluated using 2 methods: Guided Progression Analysis (GPA; Carl Zeiss Meditec, Inc) and a United States Food and Drug Administration (FDA)-suggested end point. The date of the first test showing progression after the first 2 years was considered to be the event date. Rates of change in SAP MD were calculated for the first 2 years of follow-up, and joint longitudinal survival models were used to assess the risk of faster initial MD loss for subsequent progression based on each event analysis. MAIN OUTCOME MEASURE: Risk of having an event of progression based on initial rates of SAP MD change. RESULTS: Fifty-six eye (22.8%) showed an event of progression by the GPA and 51 eyes (20.7%) did so by the FDA end point. Each 0.1-dB/year faster rate of SAP MD loss in the first 2 years was associated with a 26% increase in risk of a GPA progression end point developing (R2 = 76%) and 32% risk of an FDA-based end point developing (R2 = 83%). A reduction of 30% in the rate of MD change in the first 2 years was associated with a 20% reduction in the cumulative probability of a progression event developing over 5 years of follow-up. CONCLUSIONS: Rates of SAP MD change for eyes with glaucoma calculated over the initial 2 years of follow-up were strongly predictive of events of progression over subsequent follow-up. Our findings give support for the use of slopes of MD change as suitable end points of progression in clinical trials. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Medeiros FA, Jammal AA. Validation of Rates of Mean Deviation Change as Clinically Relevant End Points for Glaucoma Progression. Ophthalmology. 2022. PMID: 36574847. doi:10.1016/j.ophtha.2022.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。